Clinicians should evaluate for contraindications specific to GLP-1 receptor agonists, including: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 History of pancreatitis or gallbladder disease Severe gastroparesis or gastrointestinal disease History of suicidal ideation or behavior Pregnancy or planned pregnancy (pregnancy testing when appropriate) Diabetic retinopathy (requires monitoring in patients with diabetes) Baseline investigations should include TSH, free T4, complete metabolic panel, lipid profile, and hemoglobin A1c (if diabetic or prediabetic)
A minority of patients develop severe disease
For each calendar year, we calculated rates describing the overlap between semaglutide or tirzepatide prescriptions and PCOS diagnoses: Among female patients who received a semaglutide or tirzepatide prescription in a given year, we calculated the proportion who had a recorded PCOS diagnosis in or before that year
10.1038/nrneph.2016.163 55 GranataS.Dalla GassaA.TomeiP.LupoA.ZazaG
TNF-, IL-1, IL-6 kits were obtained by Krishgen Biosystem Company (Shanghai, China)
